Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Starts Construction of $150 Million Biologics Facility

publication date: Apr 30, 2015
WuXi PharmaTech, through its subsidiary WuXi Biologics, began construction of its $150 million biologics manufacturing facility in Wuxi city. According to Wuxi, the facility is slated to be the world's largest mammalian cell culture facility using disposable bioreactors, and also be the largest biologics manufacturing plant in China of any type. WuXi already provides biologic drug manufacturing services for both clinical and commercial use; the new facility will add to its commercial capacity. More details....

Stock Symbols: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital